[ad_1]
Dublin, December 9, 2021 (Global News Service) – “2021 Biosimilar Monoclonal Antibody Global Market Report: COVID-19 Growth and Changes to 2030” Report has been added to ResearchAndMarkets.com supply.
The global biosimilar monoclonal antibody market is expected to grow from USD 3.52 billion in 2020 to USD 4.33 billion in 2021, with a compound annual growth rate (CAGR) of 23%. It is estimated that by 2025, the market will reach 10.92 billion U.S. dollars, with a compound annual growth rate of 26%.
The major players in the biosimilar monoclonal antibody market are Pfizer, Novartis, Allergan, Coherus BioSciences, Biocon, Amgen, Boehringer Ingelheim, Celltrion, BioXpress Therapeutics and Intas Pharmaceuticals Limited.
The biosimilar monoclonal antibody market consists of entities (organizations, self-employed individuals and partnerships) that produce biosimilar monoclonal antibodies that sell biosimilar monoclonal antibodies and related services for the treatment of cancer, rheumatoid arthritis and Patients with chronic diseases such as autoimmune diseases.
Biosimilar monoclonal antibodies are highly similar to actual monoclonal antibodies in terms of drug quality, safety and effectiveness, and are used to enhance immunity by identifying and neutralizing foreign bodies. The market includes the revenue generated by biosimilar monoclonal antibody companies from selling these products.
The biosimilar monoclonal antibody market covered in this report is subdivided by type into synthetic chemicals, biopharmaceuticals, etc., and applied to chronic and autoimmune diseases, oncology, etc.
It is expected that strict regulations on the approval of biosimilars will hinder the growth of the biosimilar monoclonal antibody market. Governments…
The full story on Benzinga.com
[ad_2]
Source link
